12:45:32 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-08 Bokslutskommuniké 2023
2023-11-09 Kvartalsrapport 2023-Q3
2023-07-28 Kvartalsrapport 2023-Q2
2023-04-27 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-23 Halvårsutdelning AZN 20.69
2023-02-09 Bokslutskommuniké 2022
2022-11-10 Kvartalsrapport 2022-Q3
2022-08-11 Halvårsutdelning AZN 9.49
2022-07-29 Kvartalsrapport 2022-Q2
2022-04-29 Kvartalsrapport 2022-Q1
2022-04-29 Årsstämma 2022
2022-02-24 Halvårsutdelning AZN 18
2022-02-10 Bokslutskommuniké 2021
2021-11-12 Kvartalsrapport 2021-Q3
2021-08-12 Halvårsutdelning AZN 7.72
2021-07-29 Kvartalsrapport 2021-Q2
2021-05-11 Årsstämma 2021
2021-04-30 Kvartalsrapport 2021-Q1
2021-02-25 Halvårsutdelning AZN 15.76
2021-02-11 Bokslutskommuniké 2020
2020-11-05 Kvartalsrapport 2020-Q3
2020-08-13 Halvårsutdelning AZN 7.87
2020-07-30 Kvartalsrapport 2020-Q2
2020-04-29 Årsstämma 2020
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 Halvårsutdelning AZN 18.32
2020-02-14 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-08-08 Halvårsutdelning AZN 8.49
2019-07-25 Kvartalsrapport 2019-Q2
2019-04-26 Kvartalsrapport 2019-Q1
2019-04-26 Årsstämma 2019
2019-02-28 Halvårsutdelning AZN 17.46
2019-02-14 Bokslutskommuniké 2018
2018-11-08 Kvartalsrapport 2018-Q3
2018-08-09 Halvårsutdelning AZN 7.92
2018-07-26 Kvartalsrapport 2018-Q2
2018-05-18 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Halvårsutdelning AZN 14.97
2018-02-02 Bokslutskommuniké 2017
2017-11-09 Kvartalsrapport 2017-Q3
2017-08-10 Halvårsutdelning AZN 7.4
2017-07-27 Kvartalsrapport 2017-Q2
2017-04-27 Årsstämma 2017
2017-04-27 Kvartalsrapport 2017-Q1
2017-02-16 Halvårsutdelning AZN 16.57
2017-02-02 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-11 Halvårsutdelning AZN 7.81
2016-07-28 Kvartalsrapport 2016-Q2
2016-04-29 Årsstämma 2016
2016-04-29 Kvartalsrapport 2016-Q1
2016-02-18 Halvårsutdelning AZN 16.26
2016-02-04 Bokslutskommuniké 2015
2015-11-05 Kvartalsrapport 2015-Q3
2015-08-13 Halvårsutdelning AZN 7.71
2015-07-30 Kvartalsrapport 2015-Q2
2015-04-24 Kvartalsrapport 2015-Q1
2015-04-24 Årsstämma 2015
2015-02-19 Halvårsutdelning AZN 15.62
2015-02-05 Bokslutskommuniké 2014
2014-11-06 Kvartalsrapport 2014-Q3
2014-08-13 Halvårsutdelning AZN 6.2
2014-07-31 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-04-24 Årsstämma 2014
2014-02-19 Halvårsutdelning AZN 12.41
2014-02-06 Bokslutskommuniké 2013
2013-10-31 Kvartalsrapport 2013-Q3
2013-08-14 Halvårsutdelning AZN 5.92
2013-08-01 Kvartalsrapport 2013-Q2
2013-08-01 Analytiker möte 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-04-25 Årsstämma 2013
2013-02-13 Halvårsutdelning AZN 12.08
2013-01-31 Bokslutskommuniké 2012
2012-10-25 Kvartalsrapport 2012-Q3
2012-10-25 Analytiker möte 2012
2012-08-08 Halvårsutdelning AZN 6.26
2012-07-26 Kvartalsrapport 2012-Q2
2012-04-26 Årsstämma 2012
2012-04-26 Kvartalsrapport 2012-Q1
2012-02-15 Halvårsutdelning AZN 13.21
2012-02-02 Bokslutskommuniké 2011
2011-10-27 Kvartalsrapport 2011-Q3
2011-08-03 Halvårsutdelning AZN 5.33
2011-07-28 Kvartalsrapport 2011-Q2
2011-04-28 Årsstämma 2011
2011-04-28 Kvartalsrapport 2011-Q1
2011-02-02 Halvårsutdelning AZN 11.99
2011-01-27 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-04 Halvårsutdelning AZN 5.12
2010-07-29 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-03 Halvårsutdelning AZN 12.43
2010-01-28 Bokslutskommuniké 2009
2009-10-29 Kvartalsrapport 2009-Q3
2009-08-05 Halvårsutdelning AZN 4.41
2009-07-30 Kvartalsrapport 2009-Q2
2009-04-30 Kvartalsrapport 2009-Q1
2009-04-30 Årsstämma 1
2009-02-04 Halvårsutdelning AZN 12.02
2008-08-06 Halvårsutdelning AZN 3.34
2008-02-06 Halvårsutdelning AZN 8.61
2007-08-08 Halvårsutdelning AZN 3.49
2007-02-07 Halvårsutdelning AZN 8.6
2006-08-09 Halvårsutdelning AZN 3.6
2006-02-08 Halvårsutdelning AZN 7.02
2005-08-10 Halvårsutdelning AZN 2.99
2005-02-09 Halvårsutdelning AZN 4.497
2004-08-11 Halvårsutdelning AZN 2.2
2004-02-18 Halvårsutdelning AZN 3.91
2003-08-20 Halvårsutdelning AZN 2.07
2003-02-19 Halvårsutdelning AZN 3.99
2002-08-21 Halvårsutdelning AZN 2.21
2002-02-20 Halvårsutdelning AZN 5.01
2001-08-22 Halvårsutdelning AZN 2.44
2001-02-21 Halvårsutdelning AZN 4.49
2000-09-04 Halvårsutdelning AZN 2.1
2000-03-08 Halvårsutdelning AZN 4.01
1999-09-06 Halvårsutdelning AZN 1.89
1999-04-01 Split AZN 1:0.5045
1997-05-26 Split AZN 1:2
1993-06-14 Split AZN 1:5
1987-06-04 Split AZN 1:2


ListaLarge Cap Stockholm
IndustriLäkemedel & Handel
AstraZeneca är ett globalt bioläkemedelsbolag med fokus på forskning, utveckling och marknadsföring av receptbelagda läkemedel, primärt för behandling av sjukdomar inom terapiområdena som berör andningsvägar, hjärta/kärl/metabolism och cancer. Utöver huvudverksamheten är bolaget även aktiva inom autoimmunitet, neurovetenskap och infektion. AstraZeneca är verksamma inom samtliga globala regioner och har sitt huvudkontor i Cambridge, Storbritannien.
2022-11-22 08:01:22

Data will show clinical opportunity in HR-positive advanced breast cancer for potential first-in-class AKT inhibitor capivasertib and next-generation oral SERD camizestrant. Enhertu data will reinforce potential to set new standards in HER2-targetable disease. Data for antibody drug conjugate datopotamab deruxtecan will demonstrate potential in HR-positive and triple-negative breast cancer.

AstraZeneca will present new data advancing its ambition to redefine care at the 2022 San Antonio Breast Cancer Symposium (SABCS), 6-10 December 2022.

Twelve AstraZeneca medicines and potential new medicines will be featured in 55 presentations, including five oral presentations, showcasing the Company's growing leadership across different subtypes and stages of breast cancer.

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "Our data at SABCS are strong validation of our clinical strategy to provide next-generation treatment solutions for patients with nearly all major types of breast cancer. We are excited to share results from the pivotal CAPItello-291 trial, which will support the opportunity of our novel AKT inhibitor capivasertib for patients with HR-positive disease. We also look forward to presenting defining data from the SERENA-2 Phase II trial that will demonstrate the potential of our next-generation SERD camizestrant to improve upon currently available endocrine therapies for patients with ER-driven disease."

Dave Fredrickson, Executive Vice President, Oncology Business Unit, AstraZeneca, said: "As we close another year of breakthroughs in breast cancer, our presence at SABCS will showcase the opportunity for our portfolio to shape clinical practice and redefine care across subtypes and stages of this disease. Compelling results for potential new medicines capivasertib and camizestrant as well as new data from antibody drug conjugates Enhertu and datopotamab deruxtecan will underscore our focus on addressing the greatest unmet needs and delivering personalised treatment for more patients with breast cancer."

Aiming to set new standards of care across HER2-positive metastatic breast cancer

Two late-breaking presentations from the DESTINY-Breast clinical programme will highlight the efficacy of Enhertu (trastuzumab deruxtecan) treatment in patients with HER2-positive metastatic breast cancer across lines of therapy.

Updated results from the DESTINY-Breast03 Phase III trial of Enhertu versus trastuzumab emtansine (T-DM1) in patients with HER2-positive breast cancer previously treated with trastuzumab and a taxane will be presented, including updated progression-free survival (PFS) data and overall survival (OS) results.

In addition, primary results from the DESTINY-Breast02 Phase III trial will be presented, further demonstrating the clinical benefit of Enhertu compared to conventional chemotherapy-based regimens in patients with HER2-positive metastatic breast cancer previously treated with T-DM1.

Data will also be presented from the ROSET-BM retrospective study and DEBBRAH Phase II trial further confirming Enhertu activity in patients with HER2-positive or HER2-low metastatic breast cancer with active or stable brain metastases.

Reshaping treatment expectations in HR-positive advanced breast cancer

A late-breaking presentation will illustrate the Company's focus on addressing endocrine resistance in advanced HR-positive breast cancer.

Detailed data will be shared from the CAPItello-291 Phase III trial of the AKT inhibitor capivasertib in combination with Faslodex (fulvestrant) versus Faslodex alone in endocrine-resistant, HR-positive, HER2-low or negative advanced breast cancer. CAPItello-291 recently met both primary endpoints (https://www.astrazeneca.com/media-centre/press-releases/2022/capivasertib-phase-iii-trial-met-primary-endpoints.html), demonstrating improvement in PFS in the overall patient population and in a prespecified biomarker subgroup of patients whose tumours had qualifying alterations in the PIK3CA, AKT1 or PTEN genes.

Several presentations will establish the clinical potential of the next-generation oral selective oestrogen receptor degrader (SERD) camizestrant as a monotherapy or in combination for patients with oestrogen receptor positive (ER-positive) advanced breast cancer.
  • A late-breaking presentation will highlight detailed results from the positive SERENA-2 Phase II trial (https://www.astrazeneca.com/media-centre/press-releases/2022/camizestrant-significantly-improved-progression-free-survival.html) of camizestrant versus Faslodex in advanced ER-positive breast cancer.
  • Analyses from further cohorts of the SERENA-1 Phase I trial of advanced ER-positive breast cancer will also be presented, which will show the potential to combine camizestrant with abemaciclib, a CDK4/6 inhibitor.
  • A spotlight poster will feature data showing promising preclinical activity with camizestrant in ER-positive breast cancer when used in double and triple combinations with CDK4/6, mTOR, AKT or PI3K inhibitors, in ESR1 wild-type and mutated models.
Additionally, several presentations will showcase AstraZeneca's commitment to transforming the treatment landscape for HR-positive breast cancer with antibody drug conjugates (ADCs) and by identifying new tumour subtypes that may respond to targeted therapies.
  • A poster presentation of results from the TROPION-PanTumor01 Phase I trial will characterise the safety and encouraging clinical activity of datopotamab deruxtecan in patients with heavily pre-treated HR-positive, HER2-negative inoperable or metastatic breast cancer. Datopotamab deruxtecan is also being tested in these patients in earlier lines of treatment in the randomised TROPION-Breast01 Phase III trial.

  • Multiple poster presentations will share results for potential diagnostic tools to better identify and optimise treatment for patients across the spectrum of HER2 expression, including those with HER2-low tumours who may benefit from treatment with Enhertu.

  • Data from various subgroup analyses from the DESTINY-Breast04 Phase III trial will reinforce the clinical meaningfulness of HER2-low as an actionable patient segment in patients with metastatic breast cancer.

Redefining care for triple-negative breast cancer (TNBC)

Two spotlight poster discussions will share results from the BEGONIA Phase Ib/II trial testing Imfinzi (durvalumab) combinations in advanced or metastatic TNBC, showing the potential to drive improved outcomes with the addition of ADCs.

Additionally, updated results from the TROPION-PanTumor01 Phase I trial of datopotamab deruxtecan monotherapy will show encouraging and durable anti-tumour activity, and a manageable safety profile in heavily pre-treated patients with metastatic TNBC. The TROPION-Breast02 Phase III trial is evaluating datopotamab deruxtecan as 1st-line therapy for patients with metastatic TNBC.

Enhertu and datopotamab deruxtecan are developed and commercialised in collaboration with Daiichi Sankyo worldwide, except in Japan where Daiichi Sankyo maintains exclusive rights.

Key AstraZeneca presentations during SABCS 2022

Lead author Abstract title Presentation details
Krop, I Trastuzumab Presentation #GS2-01
deruxtecan vs
physician's choice Oral Presentation -
in patients with General Session 2
HER2+ unresectable
and/or metastatic 7 December 2022
breast cancer
previously treated 09:00 - 09:15 CT
with trastuzumab
emtansine: primary 15:00 - 15:15 GMT
results of the
randomized phase 3
Hurvitz, SA Trastuzumab Presentation #GS2-02
deruxtecan versus
trastuzumab Oral Presentation -
emtansine in General Session 2
patients with HER2
-positive metastatic 7 December 2022
breast cancer:
Updated survival 09:15 - 09:30 CT
results of the
randomized, phase 3 15:15 - 15:30 GMT
Takashi, Y Trastuzumab Presentation #PD7-01
deruxtecan for the
treatment of Spotlight Poster
patients with HER2 Discussion 7
-positive breast
cancer with brain 7 December 2022
leptomeningeal 17:00 CT
metastases: A
multicenter 23:00 GMT
retrospective study
(ROSET-BM study)
Hamilton, EP Dose-expansion study Presentation #PD18-11
of Trastuzumab
Deruxtecan as Spotlight Poster
monotherapy or Discussion 18
combined with
Pertuzumab in 9 December 2022
patients With
metastatic human 07:00 CT
epidermal growth
factor receptor 2 13:00 GMT
-positive (HER2+)
breast cancer in
DESTINY-Breast07 (DB
Varghese, D A real-world Presentation #P1-11-19
evidence study of
treatment patterns Poster Session 1
in patients with
HER2-positive 6 December 2022
metastatic breast
cancer who have 17:00 CT
received at least 2
-lines of therapy 23:00 GMT
Lam, C Treatment patterns Presentation #P4-03-34
and outcomes among
patients with HER2 Poster Session 4
breast cancerin the 8 December 2022
United States
07:00 CT

13:00 GMT
Henderson, M Adverse events (AEs) Presentation #P4-07-53
in phase III
clinical trials of Poster Session 4
patients with human
epidermal growth 8 December 2022
factor receptor-2
positive (HER2+) 07:00 CT
breast cancer (BC):
a meta-analysis 13:00 GMT
Lin, NU Open-label, phase Presentation #OT2-16-02
3b/4 study of
trastuzumab Ongoing Trials Poster
deruxtecan (T-DXd) Session 2
in patients with or
without baseline 7 December 2022
brain metastasis
with 17:00 CT
human epidermal 23:00 GMT
growth factor
receptor 2-positive
breast cancer:
Prat, A Determination of Presentation #HER2-18
HER2-low status in
tumors of patients HER2 Low: A Separate
with unresectable Entity Special Poster
and/or metastatic Session 
breast cancer in
DESTINY-Breast04 7 December 2022

09:45 - 11:00 CT

15:45 - 17:00 GMT
Viale, G Retrospective Study Presentation #HER2-15
to Estimate the
Prevalence and HER2 Low: A Separate
Describe the Entity Special Poster
Clinicopathological Session
Treatment Patterns, 7 December 2022
and Outcomes of HER2
-Low Breast Cancer 09:45 - 11:00 CT

15:45 - 17:00 GMT
Rüschoff, J Proficiency Presentation #HER2-13
assessment of HER2
-low breast cancer HER2 Low: A Separate
scoring with the Entity Special Poster
Ventana PATHWAY 4B5 Session 
and Dako HercepTest
HER2 assays and the 7 December 2022
impact of
pathologist training 09:45 - 11:00 CT

15:45 - 17:00 GMT
Schmid, P Trastuzumab Presentation #PD11-08
deruxtecan (T-DXd) +
durvalumab (D) as Spotlight Poster
first-line (1L) Discussion 11
treatment for
unresectable locally 8 December 2022
hormone receptor 07:00 CT
-negative (HR−),
HER2-low breast 13:00 GMT
cancer: updated
results from
BEGONIA, a phase
1b/2 study
Pérez Trastuzumab Presentation #PD7-02
-García, JM Deruxtecan in
patients with Spotlight Poster
Unstable Central Discussion 7
Nervous System
Involvement from 7 December 2022
HER2-Low Advanced
Breast Cancer: The 17:00 CT
23:00 GMT
Harbeck, N Trastuzumab Presentation #P1-11-01
deruxtecan vs
treatment of Poster Session 1
physician's choice
in patients with 6 December 2022
unresectable and/or 17:00 CT
metastatic breast
cancer: Subgroup 23:00 GMT
analyses from
Spitzmüller, Computational Presentation #P6-04-03
A pathology based HER2
expression Poster Session 6
quantification in
HER2-low breast 9 December 2022
07:00 CT

13:00 GMT
Tsirka, A High Intra- and Presentation #P6-04-17
concordance of HER2 Poster Session 6
(IHC) scores across 9 December 2022
breast cancer
samples and impact 07:00 CT
of decalcification
procedures 13:00 GMT
Globerson, Y A fully automatic Presentation #P6-04-05
intelligence system Poster Session 6
for accurate
andreproducible HER2 9 December 2022
IHC scoring in
breast cancer 07:00 CT

13:00 GMT
Kapil, A ART: Automated Presentation #P6-04-16
Region segmentation
of Tumor on HER2 Poster Session 6
-stained breast
cancer tissue 9 December 2022

07:00 CT

13:00 GMT
Hurvitz, SA TRIO-US B-12 TALENT: Presentation #GS2-03
trastuzumab Oral Presentation -
deruxtecan with or General Session 2
without anastrozole
for HER2-low, HR+ 7 December 2022
early stage breast
cancer 09:30 - 09:45 CT

15:30 - 15:45 GMT
Oliveira, M Camizestrant, a next Presentation #GS3-02
generation oral SERD
vs fulvestrant in Oral Presentation -
post-menopausal General Session 3
women with advanced
ER-positive HER2 8 December 2022
-negative breast
cancer: Results of 08:45 - 09:00 CT
the randomized,
multi-dose Phase 2 14:45 - 15:00 GMT
SERENA-2 trial
Turner, NC Capivasertib and Presentation #GS3-04
fulvestrant for
patients with Oral Presentation -
aromatase inhibitor General Session 3
-resistant hormone
receptor 8 December 2022
epidermal growth 09:15 - 09:30 CT
factor receptor 2
-negative advanced 15:15 - 15:30 GMT
breast cancer:
results from the
Phase III CAPItello
-291 trial
Meric Phase 1 TROPION Presentation #PD13-08
-Bernstam, F -PanTumor01 Study
evaluating Spotlight Poster
Datopotamab Discussion 13
Deruxtecan (Dato
-DXd) in 8 December 2022
unresectable or
metastatic hormone 17:00 CT
2-negative breast 23:00 GMT
cancer (BC)
Carnevalli, Combination of the Presentation #PD10-04
L next generation oral
SERD camizestrant Spotlight Poster
(AZD9833) with Discussion 10
CDK4/6 and mTOR/AKT
inhibitors delivers 8 December 2022
robust efficacy in a
broad range of ER+ 07:00 CT
breast tumors
13:00 GMT
Morrow, C The next generation Presentation #P3-07-13
oral selective
estrogen receptor Poster Session 3
degrader (SERD)
camizestrant 7 December 2022
(AZD9833) is active
against wild type 17:00 CT
and mutant estrogen
receptor α 23:00 GMT
Bardia, A Datopotamab Presentation #OT1-03-04
deruxtecan (Dato
-DXd), a TROP2 Ongoing Trials Poster
antibody-drug Session 1
investigators' 6 December 2022
choice of
chemotherapy in 17:00 CT
inoperable or 23:00 GMT
cancer: TROPION
Turner, NC SERENA-1: Updated Presentation #OT2-02-01
analyses from a
Phase 1 study of the Ongoing Trials Poster
next generation oral Session 2
selective estrogen
receptor degrader 7 December 2022
(AZD9833) combined 17:00 CT
with abemaciclib, in
women with ER 23:00 GMT
-positive, HER2
-negative advanced
breast cancer
TNBC and
Schmid, P Datopotamab Presentation #PD11-09
deruxtecan (Dato
-DXd) + durvalumab Spotlight Poster
(D) as first-line Discussion 11
(1L) treatment for
unresectable locally 8 December 2022
triple-negative 07:00 CT
breast cancer
(a/mTNBC): updated 13:00 GMT
results from
BEGONIA, a phase
1b/2 study
Bardia, A Datopotamab Presentation #P6-10-03
Deruxtecan (Dato
-DXd) in advanced Poster Session 6
breast cancer 9 December 2022
(TNBC): Updated
results from the 07:00 CT
-PanTumor01 Study 13:00 GMT
Copson, ER Expert consensus on Presentation #P3-05-39
the definition
ofhighrisk of Poster Session 3
recurrence inHER2
-negative eBC: a 7 December 2022
modified Delphipanel
17:00 CT

23:00 GMT
Dent, R TROPION-Breast02: Presentation #OT1-03-05
Phase 3, open-label,
randomized study of Ongoing Trials Poster
first-line Session 1
deruxtecan versus 6 December 2022
chemotherapy in
patients with 17:00 CT
locally recurrent
inoperable or 23:00 GMT
metastatic TNBC who
are not candidates
for anti-PD-(L)1
Balmaña, J OlympiaN: a phase 2, Presentation #OT2-18-02
multicenter, open
-label study to Ongoing Trials Poster
assess the efficacy Session 2
and safety of
neoadjuvant olaparib 7 December 2022
monotherapy and
olaparib plus 17:00 CT
durvalumab in
patients with BRCA 23:00 GMT
mutations and early
-stage HER2-negative
breast cancer


AstraZeneca in breast cancer

Driven by a growing understanding of breast cancer biology, AstraZeneca is starting to challenge, and redefine, the current clinical paradigm for how breast cancer is classified and treated to deliver even more effective treatments to patients in need - with the bold ambition to one day eliminate breast cancer as a cause of death.

AstraZeneca has a comprehensive portfolio of approved and promising compounds in development that leverage different mechanisms of action to address the biologically diverse breast cancer tumour environment.

With Enhertu (trastuzumab deruxtecan), a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.

In HR-positive breast cancer, AstraZeneca continues to improve outcomes with foundational medicines Faslodex (fulvestrant) and Zoladex (goserelin) and aims to reshape the HR-positive space with ngSERD and potential new medicine camizestrant as well as a potential first-in-class AKT kinase inhibitor, capivasertib. AstraZeneca is also collaborating with Daiichi Sankyo to explore the potential of TROP2-directed ADC, datopotamab deruxtecan, in this setting.

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has been studied in early and metastatic breast cancer patients with an inherited BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and Canada) continue to researchLynparza in metastatic breast cancer patients with an inherited BRCA mutation and are exploring new opportunities to treat these patients earlier in their disease.

To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is testing immunotherapy Imfinzi (durvalumab) in combination with other oncology medicines, including Lynparza and Enhertu, evaluating the potential of capivasertib in combination with chemotherapy, and datopotamab deruxtecan.

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.

The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.

AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.


AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).


For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).